Candela and InMode Announce Settlement Of Patent Infringement Lawsuit

OrthoNext Digital Platform for the JuniOrtho Plating System Receives FDA Clearance

“Together, OrthoNext and the JuniOrtho Plating System provide a complete solution for surgeons looking for a plating system to address the specific demands of advanced deformity and trauma reconstruction of the lower extremities in the pediatric population,” said Orthofix President of Global Orthopedics Paul Gonsalves.

SonarMed, New Pediatric Monitor Alerts Clinicians To Potential Airway Obstructions During Ventilation Launched

"The SonarMed airway monitoring device has revolutionized the way we care for our littlest patients. There is no other device in the world that can tell you where the endotracheal tube is located within the airway continuously in real-time, and whether the tube is obstructed or even partially occluded," said Jamie W. Powers, M.D., MBA, neonatologist at Huntington Hospital in Pasadena, California.

Syneron Medical Ltd. and Candela Corporation (collectively, “Candela”), a leading global aesthetic device company and the exclusive licensee of certain patents of General Hospital Corporation, d/b/a Massachusetts General Hospital (“MGH”), and Invasix, Inc., InMode, Ltd., and InMode MD, Ltd. (collectively, “InMode”), a leader in cutting edge minimally invasive medical solutions, announce that they have entered into a worldwide comprehensive mutual settlement agreement ending the patent disputes between the companies. Terms of the settlement agreement are not disclosed.

The mutually agreed-upon settlement, through a sublicense from Candela, allows InMode to continue to actively market its bi-polar fractional RF product line, which includes the Fractora and the Morpheus8, protecting Candela’s investment in the development of products in the long pulse category. Candela’s Profound system is the only FDA-cleared, real-time temperature-controlled device that delivers long pulses of Radio Frequency energy to create all three skin fundamentals – collagen, elastin and hyaluronic acid. InMode’s Fractora and Morpheus8 are FDA-cleared for skin ablation and resurfacing, coagulation, hemostasis and treatment of wrinkles.

Geoffrey Crouse, Chief Executive Officer of Candela, commented, “Candela is focused on science, results and trust. We invest heavily in Research and Development and will continue to enforce our intellectual property rights so that we can develop innovative technology and invest in clinical research to address unmet clinical needs in aesthetic medicine.  We are pleased to have reached a settlement with InMode on mutually-agreeable terms.”

Moshe Mizrahy, co-founder and Chief Executive Officer of InMode, commented, “InMode is a fast-growing company with an emphasis on innovation and science, having over 40 peer-reviewed publications and a strong IP portfolio. We look forward to moving on and fulfilling our mandate of launching advanced solutions for doctors and clinics worldwide.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles